Global Live Cell Encapsulation 麻豆原创 2025 by Company, Regions, Type and Application, Forecast to 2031

Publication ID:

GIR012509541

Publication Date:

January 23, 2025

Pages:

100

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Live Cell Encapsulation market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
Live cell encapsulation has long been proposed as a solution in modern medicine to many therapeutic problems. Cell encapsulation technology is used for the immobilization of cells within biocompatible and semipermeable membranes. The encapsulation of cells, instead of therapeutic products, is used to allow the delivery of molecules of interest for a longer time period as cells release these molecules of interest continuously. Furthermore, cells can be engineered for expressing the protein of interest in vivo without modifying the host鈥檚 genome. Cell encapsulation presents a significant advantage compared to protein encapsulation, as cell encapsulation allows a sustained and controlled delivery therapeutic molecules at a constant rate, thereby resulting in greater physiological concentrations.
The Live Cell Encapsulation industry can be broken down into several segments, Alginate, HEMA-MMA, etc.
Across the world, the major players cover BioTime, Reed Pacific, Viacyte, etc.
Global Live Cell Encapsulation key players include Viacyte, Inc., Living Cell Technologies Ltd., Sigilon Therapeutics, Inc, Sernova Corporation, PharmaCyte Biotech Inc, Gloriana Therapeutics, Kadimastem, Beta-O2 Technologies, Inc., Altucell, Inc., Diatranz Otsuka Ltd, etc.
This report is a detailed and comprehensive analysis for global Live Cell Encapsulation market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Live Cell Encapsulation market size and forecasts, in consumption value ($ Million), 2020-2031
Global Live Cell Encapsulation market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Live Cell Encapsulation market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Live Cell Encapsulation market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Live Cell Encapsulation
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Live Cell Encapsulation market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Viacyte, Inc., Living Cell Technologies Ltd., Sigilon Therapeutics, Inc, Sernova Corporation, PharmaCyte Biotech Inc, Gloriana Therapeutics, Kadimastem, Beta-O2 Technologies, Inc., Altucell, Inc., Diatranz Otsuka Ltd, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Live Cell Encapsulation market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Alginate
Chitosan
Cellulose
Others
麻豆原创 segment by Application
Diabetes
Cancer
Epilepsy
Parkinson
Others
麻豆原创 segment by players, this report covers
Viacyte, Inc.
Living Cell Technologies Ltd.
Sigilon Therapeutics, Inc
Sernova Corporation
PharmaCyte Biotech Inc
Gloriana Therapeutics
Kadimastem
Beta-O2 Technologies, Inc.
Altucell, Inc.
Diatranz Otsuka Ltd
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Live Cell Encapsulation product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Live Cell Encapsulation, with revenue, gross margin, and global market share of Live Cell Encapsulation from 2020 to 2025.
Chapter 3, the Live Cell Encapsulation competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Live Cell Encapsulation market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Live Cell Encapsulation.
Chapter 13, to describe Live Cell Encapsulation research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Live Cell Encapsulation by Type
1.3.1 Overview: Global Live Cell Encapsulation 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Live Cell Encapsulation Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 Alginate
1.3.4 Chitosan
1.3.5 Cellulose
1.3.6 Others
1.4 Global Live Cell Encapsulation 麻豆原创 by Application
1.4.1 Overview: Global Live Cell Encapsulation 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Diabetes
1.4.3 Cancer
1.4.4 Epilepsy
1.4.5 Parkinson
1.4.6 Others
1.5 Global Live Cell Encapsulation 麻豆原创 Size & Forecast
1.6 Global Live Cell Encapsulation 麻豆原创 Size and Forecast by Region
1.6.1 Global Live Cell Encapsulation 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Live Cell Encapsulation 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Live Cell Encapsulation 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Live Cell Encapsulation 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Live Cell Encapsulation 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Live Cell Encapsulation 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Live Cell Encapsulation 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Viacyte, Inc.
2.1.1 Viacyte, Inc. Details
2.1.2 Viacyte, Inc. Major Business
2.1.3 Viacyte, Inc. Live Cell Encapsulation Product and Solutions
2.1.4 Viacyte, Inc. Live Cell Encapsulation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Viacyte, Inc. Recent Developments and Future Plans
2.2 Living Cell Technologies Ltd.
2.2.1 Living Cell Technologies Ltd. Details
2.2.2 Living Cell Technologies Ltd. Major Business
2.2.3 Living Cell Technologies Ltd. Live Cell Encapsulation Product and Solutions
2.2.4 Living Cell Technologies Ltd. Live Cell Encapsulation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Living Cell Technologies Ltd. Recent Developments and Future Plans
2.3 Sigilon Therapeutics, Inc
2.3.1 Sigilon Therapeutics, Inc Details
2.3.2 Sigilon Therapeutics, Inc Major Business
2.3.3 Sigilon Therapeutics, Inc Live Cell Encapsulation Product and Solutions
2.3.4 Sigilon Therapeutics, Inc Live Cell Encapsulation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Sigilon Therapeutics, Inc Recent Developments and Future Plans
2.4 Sernova Corporation
2.4.1 Sernova Corporation Details
2.4.2 Sernova Corporation Major Business
2.4.3 Sernova Corporation Live Cell Encapsulation Product and Solutions
2.4.4 Sernova Corporation Live Cell Encapsulation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Sernova Corporation Recent Developments and Future Plans
2.5 PharmaCyte Biotech Inc
2.5.1 PharmaCyte Biotech Inc Details
2.5.2 PharmaCyte Biotech Inc Major Business
2.5.3 PharmaCyte Biotech Inc Live Cell Encapsulation Product and Solutions
2.5.4 PharmaCyte Biotech Inc Live Cell Encapsulation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 PharmaCyte Biotech Inc Recent Developments and Future Plans
2.6 Gloriana Therapeutics
2.6.1 Gloriana Therapeutics Details
2.6.2 Gloriana Therapeutics Major Business
2.6.3 Gloriana Therapeutics Live Cell Encapsulation Product and Solutions
2.6.4 Gloriana Therapeutics Live Cell Encapsulation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Gloriana Therapeutics Recent Developments and Future Plans
2.7 Kadimastem
2.7.1 Kadimastem Details
2.7.2 Kadimastem Major Business
2.7.3 Kadimastem Live Cell Encapsulation Product and Solutions
2.7.4 Kadimastem Live Cell Encapsulation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Kadimastem Recent Developments and Future Plans
2.8 Beta-O2 Technologies, Inc.
2.8.1 Beta-O2 Technologies, Inc. Details
2.8.2 Beta-O2 Technologies, Inc. Major Business
2.8.3 Beta-O2 Technologies, Inc. Live Cell Encapsulation Product and Solutions
2.8.4 Beta-O2 Technologies, Inc. Live Cell Encapsulation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Beta-O2 Technologies, Inc. Recent Developments and Future Plans
2.9 Altucell, Inc.
2.9.1 Altucell, Inc. Details
2.9.2 Altucell, Inc. Major Business
2.9.3 Altucell, Inc. Live Cell Encapsulation Product and Solutions
2.9.4 Altucell, Inc. Live Cell Encapsulation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Altucell, Inc. Recent Developments and Future Plans
2.10 Diatranz Otsuka Ltd
2.10.1 Diatranz Otsuka Ltd Details
2.10.2 Diatranz Otsuka Ltd Major Business
2.10.3 Diatranz Otsuka Ltd Live Cell Encapsulation Product and Solutions
2.10.4 Diatranz Otsuka Ltd Live Cell Encapsulation Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Diatranz Otsuka Ltd Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Live Cell Encapsulation Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Live Cell Encapsulation by Company Revenue
3.2.2 Top 3 Live Cell Encapsulation Players 麻豆原创 Share in 2024
3.2.3 Top 6 Live Cell Encapsulation Players 麻豆原创 Share in 2024
3.3 Live Cell Encapsulation 麻豆原创: Overall Company Footprint Analysis
3.3.1 Live Cell Encapsulation 麻豆原创: Region Footprint
3.3.2 Live Cell Encapsulation 麻豆原创: Company Product Type Footprint
3.3.3 Live Cell Encapsulation 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Live Cell Encapsulation Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Live Cell Encapsulation 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Live Cell Encapsulation Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Live Cell Encapsulation 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Live Cell Encapsulation Consumption Value by Type (2020-2031)
6.2 North America Live Cell Encapsulation 麻豆原创 Size by Application (2020-2031)
6.3 North America Live Cell Encapsulation 麻豆原创 Size by Country
6.3.1 North America Live Cell Encapsulation Consumption Value by Country (2020-2031)
6.3.2 United States Live Cell Encapsulation 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Live Cell Encapsulation 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Live Cell Encapsulation 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Live Cell Encapsulation Consumption Value by Type (2020-2031)
7.2 Europe Live Cell Encapsulation Consumption Value by Application (2020-2031)
7.3 Europe Live Cell Encapsulation 麻豆原创 Size by Country
7.3.1 Europe Live Cell Encapsulation Consumption Value by Country (2020-2031)
7.3.2 Germany Live Cell Encapsulation 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Live Cell Encapsulation 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Live Cell Encapsulation 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Live Cell Encapsulation 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Live Cell Encapsulation 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Live Cell Encapsulation Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Live Cell Encapsulation Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Live Cell Encapsulation 麻豆原创 Size by Region
8.3.1 Asia-Pacific Live Cell Encapsulation Consumption Value by Region (2020-2031)
8.3.2 China Live Cell Encapsulation 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Live Cell Encapsulation 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Live Cell Encapsulation 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Live Cell Encapsulation 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Live Cell Encapsulation 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Live Cell Encapsulation 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Live Cell Encapsulation Consumption Value by Type (2020-2031)
9.2 South America Live Cell Encapsulation Consumption Value by Application (2020-2031)
9.3 South America Live Cell Encapsulation 麻豆原创 Size by Country
9.3.1 South America Live Cell Encapsulation Consumption Value by Country (2020-2031)
9.3.2 Brazil Live Cell Encapsulation 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Live Cell Encapsulation 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Live Cell Encapsulation Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Live Cell Encapsulation Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Live Cell Encapsulation 麻豆原创 Size by Country
10.3.1 Middle East & Africa Live Cell Encapsulation Consumption Value by Country (2020-2031)
10.3.2 Turkey Live Cell Encapsulation 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Live Cell Encapsulation 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Live Cell Encapsulation 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Live Cell Encapsulation 麻豆原创 Drivers
11.2 Live Cell Encapsulation 麻豆原创 Restraints
11.3 Live Cell Encapsulation Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Live Cell Encapsulation Industry Chain
12.2 Live Cell Encapsulation Upstream Analysis
12.3 Live Cell Encapsulation Midstream Analysis
12.4 Live Cell Encapsulation Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

Viacyte, Inc.
Living Cell Technologies Ltd.
Sigilon Therapeutics, Inc
Sernova Corporation
PharmaCyte Biotech Inc
Gloriana Therapeutics
Kadimastem
Beta-O2 Technologies, Inc.
Altucell, Inc.
Diatranz Otsuka Ltd

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.